ABO Retina and Vitreous Disorders 2

Question 1

In DRCR.net Protocol T, for center-involved diabetic macular edema with baseline visual acuity of 20/50 or worse, which agent produced the greatest 1-year visual gain?

Accepted Answer

Aflibercept

Answer

Protocol T showed aflibercept was superior at 1 year in eyes with worse baseline vision (20/50 or worse), with the difference narrowing by 2 years.

Question 2

A 78-year-old presents with sudden painless monocular vision loss and a cherry-red spot. What is the most urgent next step in workup?

Accepted Answer

ESR, CRP, and platelet count to evaluate for giant cell arteritis

Answer

Arteritic CRAO must be excluded immediately in older patients because the fellow eye is at high risk without prompt corticosteroids.

Question 3

Which feature most strongly predicts successful pharmacologic release of vitreomacular traction with ocriplasmin?

Accepted Answer

Absence of an epiretinal membrane

Answer

Ocriplasmin works best in phakic, younger patients with focal adhesion ≤1500 µm and no epiretinal membrane.

Question 4

According to ETROP, which retinopathy of prematurity finding meets type 1 criteria for treatment?

Accepted Answer

Zone II, stage 2 with plus disease

Answer

Type 1 ROP includes zone I any stage with plus, zone I stage 3 without plus, and zone II stage 2 or 3 with plus.

Question 5

Which exposure is most strongly associated with central serous chorioretinopathy?

Accepted Answer

Systemic or topical corticosteroids

Answer

Exogenous and endogenous corticosteroids are the best-established risk factor for CSC.

ABO - American Board of Ophthalmology Practice Test

ABO - American Board of Ophthalmology Practice Test

ABO Retina and Vitreous Disorders 2